Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Journal of Clinical Oncology - e15055 Background: There is immune evasion and resistance to checkpoint inhibitors (CPI). Programmed death-ligand 1 (PD-L1) and Tumor mutational burden (TMB) might help us...

  • Serine/threonine kinase 11 (STK11) mutations & immunotherapy resistance in NSCLC [May 25, 2020] Uba et al. #ASCO20 Abst e15055 https://t.co/3XJMI8cdAX #lcsm #PrecisionMedicine #ImmunoOnc 31/127 STK11 mut, 14 STK11+KRAS mut (SKM group), & 10 SKMP (STK11+KRAS mut+PD-L1 (-))

Oncology Tube - Denise Manon Langabeer, MBA, Ph.D. of MD Anderson gives an overview from ASCO 2020 the abstract entitled Are symptoms distinguishable in ovarian cancer? A...

Oncology Tube - Nikhil C. Munshi, MD of Dana-Farber Cancer Institute discusses ASCO20 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and...

Meeting Library | Meeting Library

posted 3 weeks

Mashup Score: 2

meetinglibrary.asco.org - 2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved...

Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma

posted 2 weeks

Mashup Score: 1

OncLive - Marc J. Braunstein, MD, PhD, highlights pivotal research on the use of triplet and quadruplet regimens in the up-front and relapsed/refractory multiple myeloma treatment...

Oncology Tube - Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer US Oncology Research discusses ASCO 2020 A phase III randomized controlled trial of secondary surgical cytoreduction...

Andrzej Jakubowiak, MD, Ph.D. @UCCancerCenter #ASCO20 #multiplemyeloma Update of the phase 1/2 EVOLVE study

posted 2 weeks

Mashup Score: 1

Oncology Tube - Andrzej Jakubowiak, MD, Ph.D. of the University of Chicago Comprehensive Cancer Center speaks on the ASCO 2020 abstract Orvacabtagene autoleucel (orva-cel), a B-cell maturation...

Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies – The ASCO Post

posted 2 weeks

ascopost.com - “Declare the past, diagnose the present, foretell the future.” ­—Hippocrates Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression...

Oncology Tube - Paul G. Richardson, MD of Dana-Farber Cancer Institute explains the abstract entitled First-in-human phase I study of the novel CELMoD agent CC-92480 combined with...

Neoadjuvant, Adjuvant Data Provide Evidence of Curative Potential in Advanced Melanoma

posted 2 weeks

OncLive - Michael B. Atkins, MD, discusses the clinical impact of key adjuvant and neoadjuvant data in the melanoma space, as well as the risks and...

  • Long-term data presented at #ASCO20 demonstrated sustained RFS benefit with adjuvant therapy in patients with advanced melanoma, providing further evidence of the curative potential of postoperative therapy. @LombardiCancer #melnm https://t.co/ZlxBWKD2fP